Clinical value of p53, c‐erbB‐2, CEA and CA125 regarding relapse, metastasis and death in resectable non‐small cell lung cancer
Open Access
- 29 August 2003
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 107 (5) , 781-790
Abstract
The prognostic value of p53 and c‐erbB‐2 immunostaining and preoperative serum levels of CEA and CA125 was investigated in a prospective multicentric study including 465 consecutive non‐small cell lung cancer (NSCLC) patients with resectable tumors. Four end‐points were used: lung cancer death, first relapse (either locoregional or metastasis), loco‐regional recurrence and metastasis development. Standard statistical survival methods (Kaplan‐Meier and Cox regression) were used. The specificity of the prognostic effect across different types of tumors was also explored, as had been planned in advance. Our results showed, once again, that pathological T and N classifications continue to be the strongest predictors regarding either relapse or mortality. Three of the studied markers seemed to add further useful information, however, but in a more specific context. For example, increased CEA concentration defined a higher risk population among adenocarcinomas but not among people with squamous tumors; and p53 overexpression implied a worse prognosis mainly in patients with well differentiated tumors. The analysis of type of relapse proved to be very informative. Thus, CA125 level was associated with a worse prognosis mainly related with metastasis development. Another interesting result was the influence of smoking, which showed a clear dose‐response relationship with the probability of metastasis. For future studies, we recommend the inclusion of different endpoints, namely considering the relationship of markers with the type of relapse involved in lung‐cancer recurrence. They can add useful information regarding the complex nature of prognosis.Keywords
Funding Information
- Health Research Fund of the Spanish Ministry of Health (97/0001)
This publication has 43 references indexed in Scilit:
- Apoptotic tumor-cell death in response to cell proliferation is influenced by p53 status in resected non-small cell lung cancerLung Cancer, 2002
- Prognostic factors in clinical stage I non–small cell lung cancerThe Annals of Thoracic Surgery, 1999
- Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinomaOncogene, 1999
- Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cellsOncogene, 1998
- Prognostic Biomarker Study in Pathologically Staged N1 Non-Small Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- Tumor angiogenesis and biologic markers in resected stage I NSCLCEuropean Journal of Cardio-Thoracic Surgery, 1997
- p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinomaEuropean Journal of Cardio-Thoracic Surgery, 1997
- Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancerLung Cancer, 1993
- Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinomaEuropean Journal of Cancer and Clinical Oncology, 1991
- A class of rank test procedures for censored survival dataBiometrika, 1982